Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.
Metrics to compare | VVY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVVYPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.1x | −2.6x | −0.6x | |
PEG Ratio | −0.07 | 0.01 | 0.00 | |
Price/Book | 5.4x | 1.0x | 2.6x | |
Price / LTM Sales | - | 20.4x | 3.3x | |
Upside (Analyst Target) | 394.2% | 144.7% | 38.7% | |
Fair Value Upside | Unlock | 7.8% | 5.1% | Unlock |